Video

Dr. Weber discusses cardiovascular safety of vibegron in patients with OAB

Author(s):

Urology Times staff

“The take-home message is vibegron is a very safe drug and there are no concerns about any kind of cardiovascular adverse effects,” says Michael A. Weber, MD.

In this video, Michael A. Weber, MD, discusses the takeaways of the study, “Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind study,” presented at the 2021 American Urological Association Annual Meeting. Weber is a professor of medicine and associate dean of research at Downstate College of Medicine, State University of New York, Brooklyn, New York.

Related Videos
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
Dr Louise Kostos answers a question during a Zoom video interview
Illustration of prostate | Image Credit: © Judith - stock.adobe.com
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
FDA greenlights pivotal trial of Voro Urologic Scaffold for postprostatectomy SUI
March 4th 2025

FDA greenlights pivotal trial of Voro Urologic Scaffold for postprostatectomy SUI

Hannah Clarke
The ARID II trial is assessing the safety and effectiveness of the device in men who are scheduled to undergo robotic-assisted radical prostatectomy.
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff
“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
Survey data highlights substantial impact of postpartum incontinence
February 11th 2025

Survey data highlights substantial impact of postpartum incontinence

Hannah Clarke
Overall, 85% of respondents indicated they experienced frequent bladder leaks.
Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB
March 18th 2022

Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

Urology Times staff
“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.
ROBUST I: Optilume maintains durable efficacy, safety for urethral strictures
January 20th 2025

ROBUST I: Optilume maintains durable efficacy, safety for urethral strictures

Hannah Clarke
Functional success was achieved in 58% of patients at 5-year follow-up.
Sunobinop shows promise in phase 1b trial for overactive bladder
January 7th 2025

Sunobinop shows promise in phase 1b trial for overactive bladder

Hannah Clarke
Sunobinop resulted in a reduction in urinary urgency, urinary frequency, and incontinence episodes over the treatment period compared with placebo.
© 2025 MJH Life Sciences

All rights reserved.